Dy G R, Bloom E J, Ijelu G K, Merritts G W, Kramer M S, Raja R M
Kraftsow Division of Nephrology, Albert Einstein Medical Center, Philadelphia 19141.
ASAIO Trans. 1991 Jul-Sep;37(3):M274-5.
The use of recombinant human erythropoietin (r-HuEPO) corrects the anemia of chronic hemodialysis (HD) patients and improves their quality of life. The role of r-HuEPO in the genesis of graft thrombosis is controversial. A retrospective study was conducted of 46 stable chronic HD patients receiving r-HuEPO. It showed an increase in graft thrombosis in those who received the drug.
重组人促红细胞生成素（r-HuEPO）的使用可纠正慢性血液透析（HD）患者的贫血并改善其生活质量。r-HuEPO在移植血管血栓形成过程中的作用存在争议。对46例接受r-HuEPO治疗的稳定慢性HD患者进行了一项回顾性研究。结果显示，接受该药物治疗的患者移植血管血栓形成有所增加。
